key: cord-0967789-282t68oe
authors: Dimeglio, Chloé; Herin, Fabrice; Miedougé, Marcel; Martin-Blondel, Guillaume; Soulat, Jean-Marc; Izopet, Jacques
title: Protection of healthcare workers against SARS-CoV-2 reinfection
date: 2021-01-27
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab069
sha: c920bb1c9ee35fa6489474b68f0886f7d558771b
doc_id: 967789
cord_uid: 282t68oe

nan

A c c e p t e d M a n u s c r i p t Dear Editor, Recent reports of SARS-CoV-2 reinfection have raised questions as to whether and to what degree a first infection protects against reinfection [1, 2] . This is particularly important for healthcare workers (HCW) as they are always in the front line combatting both the present epidemic and any new waves of SARS-CoV-2 infection. These workers can also transmit the virus to co-workers and hospitalized susceptible patients. In their recent study, Lumley et al [3] presented 6 months of data from a longitudinal seroprevalence study of UK HCW and showed that SARS-CoV-2 anti-nucleocapsid antibodies wane within months.

We screened 8758 French HCW for total serum SARS-CoV-2 anti-spike antibodies between June 10 and July 10, 2020, after the first epidemic wave, and the end of first lockdown using a quantitative enzyme-linked immunosorbent assay (ELISA) (Wantai Biological Pharmacy Enterprise Co., Ltd, China). Their neutralizing antibody titers were determined with a virus neutralisation assay [4] . The incidence of SARS-CoV-2 during the second epidemic wave was determined with a nucleic-acid amplification method on nasopharyngeal swab sample [5] taken from all symptomatic individuals and those who had been in contact with a symptomatic individual. All ELISA-positive personnel identified by the first serologic screening were re-tested from November 30 to December 9 to determine the evolution of SARS-CoV-2 antibodies. This study was approved by the French Research Ethics Committee Est-III (COVID BioToul, ID-RCB 2020-A01292-37, ClinicalTrials.gov Identifier: NCT04385108). (Table 1) included two with very low or undetectable titers of neutralizing antibodies after the first infection, and three with above-median titers (median 16). Three re-infected subjects were symptomatic A c c e p t e d M a n u s c r i p t but only one had a significantly increased (> 4-fold) neutralizing antibody titer. The other two re-infections were asymptomatic with no significant change in neutralizing antibodies (Table 1) The absence of decrease in neutralizing antibodies following SARS-CoV-2 infections, contrary to what have been previously reported [6] , could be due to recall responses during the second epidemic wave. Our data indicate that an initial SARS-CoV-2 infection protected HCW against reinfection for at least 167 days. However a protective neutralizing antibody level could not be determined. These findings could be used to compare the immunity developed after a natural infection with that conferred by current SARS-CoV-2 vaccines.

A c c e p t e d M a n u s c r i p t M a n u s c r i p t 

The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers

Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France

Evaluation of the Aptima™ transcriptionmediated amplification assay (Hologic®) for detecting SARS-CoV-2 in clinical specimens

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

The English text was edited by Dr Owen Parkes. We thank the CRB TBR, the Clinical Research Center 1436 and the Delegation for clinical research and innovation of the Toulouse University Hospital for their highly valuable implication.

The authors declare no conflict of interest A c c e p t e d M a n u s c r i p t